Hypoxia and hypoxia-inducible factors in glioblastoma multiforme progression and therapeutic implications.

Abstract

Glioblastoma multiforme (GBM) is the most malignant and aggressive primary brain tumor in humans, with a uniformly poor prognosis. Hypoxia is a predominant feature in GBM and its microenvironment; it is associated with the tumor growth, progression and resistance to conventional therapy of cancers. Hypoxia-inducible factors (HIFs) are the master regulators of the transcriptional response to hypoxia in tumor cells and their microenvironment. Numerous studies indicated that hypoxia and HIFs played pivotal roles in the initiation, progression, therapy resistance and recurrence of GBM and maintained the phenotype of glioma stem cells (GSCs), which makes the prognosis of GBM patients worse. This review summarized the current research advance of hypoxia and HIFs in GBM progression and therapeutic implications, which will provide a better understanding of the contribution of hypoxia and HIFs to GBM initiation and progression and highlight that HIFs might be taken as the attractive molecular target approaches for GBM therapeutics.

• Authors: Liuqi Yang, Caiyu Lin, Li Wang, Huijie Guo, Xiujie Wang
• Journal: Experimental cell research (Exp Cell Res) Vol. 318 Issue 19 Pg. 2417-26 (Nov 15 2012) ISSN: 1090-2422 [Electronic] United States
• PMID: 22906859 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2012 Elsevier Inc. All rights reserved.

Chemical References

• Carrier Proteins
• Intracellular Signaling Peptides and Proteins
• Ribonucleoproteins, Small Nuclear
• SART1 protein, human

Topics

• Animals
• Brain Neoplasms (metabolism, pathology)
• Carrier Proteins (metabolism)
• Cell Hypoxia (physiology)
• Glioblastoma (metabolism, pathology)
• Humans
• Intracellular Signaling Peptides and Proteins
• Neoplastic Stem Cells (metabolism, pathology)
• Prognosis
• Ribonucleoproteins, Small Nuclear